Yang Lei, Min Yiduo, Jia Zhiyan, Wang Yupeng, Zhang Rihui, Sun Bitong
Department of Ophthalmology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Department of Biostatistics, Harbin Medical University, Harbin, Heilongjiang, China.
Cost Eff Resour Alloc. 2022 Jun 25;20(1):27. doi: 10.1186/s12962-022-00363-2.
The misconception of the purpose of strabismus treatment has, on the one hand, affected the motivation of strabismus patients to seek care and, on the other hand, has resulted in strabismus not being covered by health insurance, both of which interact to limit the motivation of strabismus patients and also impose a financial burden on strabismus patients. Previous studies on the cost of strabismus had only addressed the cost utility and functional and psychosocial benefits of strabismus surgery. The aim of this study was to estimate the direct medical expenditure incurred for strabismus surgery and analyze the trend for the period 2014-2019 using the data collected by local eye hospitals in northeast China.
This study was based on 6-year strabismus medical expenditure data collected from the eye hospital of the first affiliated hospital of Harbin medical university, covering 3596 strabismus patients who had strabismus surgery. All medical expenditure data were adjusted to 2014 using China's annual consumer price index to remove the effects of inflation.
The average direct medical expenditure for strabismus cares (in 2014) was 5309.6 CNY (US$870.4), and the annual growth rates from 2015 to 2019 (compared with the previous year) were 9.3, 7.7, 21.7, 14.5, and 4.3%, respectively. Surgical expenses accounted for the highest proportion (33.1%) of the total medical expenses followed by examinations expenses (19.7%) and medical consumables expenses (18.7%). The regression coefficient for general anaesthesia was 1804.5 and age was less than 0.
The average direct medical expenditure for strabismus increases year by year, and the growth rate is rapid. Anesthesia was the most important factor increasing medical cost, and age was negatively correlated with cost.
斜视治疗目的的误解，一方面影响了斜视患者寻求治疗的积极性，另一方面导致斜视未被纳入医保范围，这两方面相互作用，既限制了斜视患者的就医积极性，又给斜视患者带来经济负担。以往关于斜视治疗费用的研究仅涉及斜视手术的成本效用以及功能和心理社会效益。本研究旨在利用中国东北地区当地眼科医院收集的数据，估算斜视手术的直接医疗支出，并分析2014 - 2019年期间的变化趋势。
本研究基于哈尔滨医科大学附属第一医院眼科6年的斜视医疗支出数据，涵盖3596例接受斜视手术的患者。所有医疗支出数据均使用中国年度消费价格指数调整至2014年水平，以消除通货膨胀的影响。
斜视治疗的平均直接医疗支出（2014年）为5309.6元人民币（870.4美元），2015年至2019年的年增长率（与上一年相比）分别为9.3%、7.7%、21.7%、14.5%和4.3%。手术费用在总医疗费用中占比最高（33.1%），其次是检查费用（19.7%）和医用耗材费用（18.7%）。全身麻醉的回归系数为1804.5，年龄的回归系数小于0。
斜视的平均直接医疗支出逐年增加，且增长速度较快。麻醉是增加医疗费用的最重要因素，年龄与费用呈负相关。
